Nunzia Pharmaceutical Corporation (CE) (NUNZ) Quote

$NUNZ Nunzia Pharmaceutical Corporation (OTC:NUNZ), an Emerging Leader in Innovative Pharmaceutical and Nutraceuticals, has Signed a Licensing Agreement with Michael Mitsunaga for the Exclusive Patent Rights to his IV BLOOD WARMER
Press Release | 08/06/2021
SAN CLEMENTE, CA, Aug. 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Nunzi Pharmaceutical Corporation (OTC:NUNZ) entered into a License Agreement with Michael Mitsunaga as stated in the 8K filing of 08/05/2021.

Under the terms of the Agreement, Nunzia has the exclusive license to use the following items of intellectual property: IV BLOOD WARMING SYSTEM that is adaptable to handle many of the procedures that are performed in the medical field for the prevention of hypothermia. Medical research has shown that there is a large and growing need for a small, portable fluid warmer to combat the occurrence of hypothermia in the medical and paramedical fields. Recognizing this critical need. The IV Fluid Warmer is a portable, reusable 110V, AC-powered IV warmer product that will preheat intravenous solutions at the point of infusion. It has an output temperature range of 37°C to 41°C. The system shuts off automatically at 44°C to prevent overheating of the unit. The fluid warmer contains a disposable cartridge that can be recycled or returned for disposal. The device is UL and FDA approved and PATENT No.6,788,885 B2

Nunzia sees the future of Pharmaceuticals, Nutraceuticals and Health Care by expanding ways to help save lives.

Nunzia Pharmaceutical Corporation (OTC: NUNZ), is a leader in innovative pharmaceutical and nutraceutical based therapies for the treatment of behavioral anxiety symptoms of Autistic Spectrum of Disorders (ASD) and other anxiety disorders.

Current treatments for ASDs have had limited efficacy, with broad acting drugs such as antidepressants, antipsychotics, SSRIs and amphetamines being employed to varying and inconsistent treatment results. In addition to the unmet treatment needs for ASDs, NUNZIA also broadly treats a wide range of related anxiety disorders -- from ADHD which affects 4.8% of US adults and 8.7% of adolescents; to anxiety disorders (generalized, panic, and phobia related) that impact over a third of US adults and adolescents; and depressive disorders affecting up to 7.1% of the US adult population.

NUNZIA is currently available as a nutraceutical supplement, with prescribed and over-the-counter pharmaceutical treatments planned, and is unique within this space as a positive treatment quite unlike other drugs and supplements on the market. With no known negative side effects, no known addictions, and no clinical reaction to alcohol -- NUNZIA is one of the safest treatments on the market with no known adverse effects on vital organs.

NUNZIA nutraceuticals are a combination of 16 vitamins, minerals, and herbs which directly focus and target the hippocampus area of the brain, where all anxiety-based disorders begin -- NUNZIA directly targets anxiety in the hippocampus, improving the function, which is a primary cause of the affiliations and compulsory disorders present in ASDs and anxiety disorders. Treatment The NUNZIA supplement with NUNZIA has demonstrated positive results for affected patients, increased memory, improved fine motor skills and increased speech ability while decreasing the anxiety, stress, fixations, and fidgeting that complicates social interactions and life with ASDs and other anxiety disorders.

This treatment methodology represents a revolutionary departure from current drug protocols -- which are used to control and manage the symptoms of the disorder -- NUNZIA, by contrast, is the only known drug on the market to address the underlying structure of the hippocampus, treating the symptoms of these disorders instead of merely controlling them. The effects of NUNZIA have been profound, with approximately 80% of patients benefiting, with efficacy in as short as 24 to 96 hours. According to Nunzia CEO, Charles Strongo, "We have seen substantial improvements in patient's social behavior and development, reduced anxiety and "acting out", and dramatically improved quality of life for our patients and their families; all without the shotgun effect of drugging or sedating the patient. We believe that NUNZIA is a unique and novel approach to ASD and other anxiety disorder treatment -- and that in concert with therapeutic behavioral treatments, NUNZIA offers new hope for a better life to millions of children and their families."

NUNZIA is currently available as a nutraceutical supplement direct to consumers via the Company's website, www.nunziapharma.com, with wholesale distribution announcements coming shortly. Nunzia Pharmaceutical Corporation is also developing over-the-counter and pharmaceutical drug formulations of NUNZIA to better address target markets in a rapidly growing ASD therapeutic space that is expected to reach $4.6 billion in annual revenues by 2026, from approximately $3.29 billion in 2019.

About Nunzia Pharmaceutical Corporation

Nunzia Pharmaceutical Corporation is the leader in the development and delivery of innovative pharmaceutical and nutraceutical-based therapies for the behavioral symptoms of Autistic Spectrum Disorder and related conditions, such as Fragile X syndrome, as well as more common anxiety-based disorders. Its landmark offering, NUNZIA, is an innovative product that promises to fundamentally revolutionize the treatment space for these conditions. Nunzia is committed to improving the lives of children and families suffering from ASDs and anxiety-based disorders. Nunzia is a proud partner of the Autism Fragile X-Foundation, a 501 c (3) non-profit dedicated to the treatment and management of ASD patients and their families. For additional information, visit www.nunziapharma.comor follow us on Twitter.

Contact:
Michael Mitsunaga
Nunzia Pharmaceutical Corporation
MMitsunaga@NunziaPharma.com; NunziaRX@gmail.com
714-609-9117
www.nunziapharma.com

Forward-Looking Statements

This press release contains "forward-looking statements.” Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with OTC Markets, including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

$NUNZ: SO is it still Nunzia Pharma ??????



Website is alive & Kicking.


https://nunziapharma.com/




What is IKR ?



GO $NUNZ

ikr, so juicy. Read this yet?

NUNZ Form 10-12G/A

IKR, so juicy.

Nunzia's Form 10-15G/A

$NUNZ: Blank-Check Company, Shell, $0 Assets


And its trading at $11.63 / share ?



Ok then.

VGCPD changed to NUNZ:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Arizona Gold and Onyx Mining Co. changed to Nunzia Pharmaceutical Corp. and a one for 7,000 reverse split.

Mining to pharmaceuticals and a one for 7,000 R/S ??????????????? Sure, looks legit to me...good grief.

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Not for long. 1:7000 R/S coming.

https://backend.otcmarkets.com/otcapi/company/financial-report/224278/content

$VGCP under a penny.



Grabbing these on bid

Sry just saw that. This is great news. Watching for bid support.

I already posted the link.
What are you talking about.
just go to OTC Markets and find yourself

Hey, can you post the link instead of a random quote please?

Pink Current page.
https://www.otcmarkets.com/stock/VGCP/overview

Plan of Operation, bottom of page 11
file:///C:/Users/rlee/AppData/Local/Temp/SECFiling_13467285-1.pdf

pdf's don't have click links. Copy and paste into browser

Can you post the link?

Seriously?!! YAY! Checking

Pink Current now and waiting on news on company direction

Plan of Operation

Our current business plan is to identify and negotiate with a business target for the merger of that entity with and into our company. 
In certain instances, a target company may wish to become a subsidiary of ours or may wish to 
contribute or sell assets to us rather than to merge. No assurances can be given that we will be successful in identifying or negotiating with any target company. We seek to provide a method for a foreign or domestic private company to become a reporting or public company whose securities are qualified for trading in the United States secondary markets.

$VGCP

Share cancellation appears to have gone into effect. This should cause faster movement on the next update.

Looks like they are getting caught up on filings, getting ready to make a move

Very. Watch more news come out today or tomorrow. They have provided updates very reliably. I'm surprised people aren't jumping on it.

A very sweet SS here

$VGCP Updated float as per filing, 37.9 million!

Float is 37,802,917 according to filing put out last night.

https://backend.otcmarkets.com/otcapi/company/financial-report/223454/content

$VGCP

Owners control over 70 million of the 129 million O/S
$VGCP

VGCP Quarterly and annual report filings posted late after hours on otcmarkets.


https://www.otcmarkets.com/stock/VGCP/security

We are getting close...

What news is pending with VGCP?

Is it 2020 already?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143976473

In 2020 this stock will soar...

As I said one year ago, this stock will explote the pockets of the investor with money!!!

$VGCP in on huge relative volume and news pending!!

$VGCP, nice volume spike on the chart. looks like updates on the way for this dormant ticker

Quietly waking up. (:>)

.0066 8K out

Cancellation of Shares Registered on Form S-8

On April 13, 2019 the Board of Directors unanimously voted to cancel all 20,000,000 shares of common stock which had been registered with the Securities and Exchange Commission on Form S-8. On May 6, 2019 the transfer agent for the Company cancelled all such shares and they were returned to the Treasury.

https://www.otcmarkets.com/filing/html?id=13478629&guid=RwvyUpTtiuEOD3h

Means OS is around 127 million shares

In 2020 this stock will soar...

$MG* 0N ...better play imho

VGCP~~APPLICABLE ONLY TO CORPORATE ISSUERS



As of May 8, 2018, there were 112,410,467 shares of registrant’s common stock outstanding.

Yeah saw that but that only takes place if FINRA APPROVES it. Lets see if they do.

the pending R/S per Filing probably the reason why VGCP not jump higher.

LOL! They're hitting

Tons of more filings hitting wow!

44 more FILINGS to come if my math is correct!

VGCP sure has a lot of catching up to do. Will be watching.

Whole lot of filings just hit this afternoon. Looks like they wanting to go current.

VGCP 003 +30%

VGCP first filings after 7 years of shell >>> 143M O/S https://www.otcmarkets.com/stock/VGCP/disclosure

VGCP 005 +127%

R/s coming, stay away

Read this, first page under Security Information at the bottom https://backend.otcmarkets.com/otcapi/company/financial-report/188713/content

what do you think will happen with this stock?

hi, what do you thinks going on with VGCP? thanks

Bidding to see if I can fill some more, trades thin $vgcp